Cytosorbents (NASDAQ:CTSO) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued to investors on Thursday morning. The firm issued a hold rating on the medical research company’s stock.

Separately, HC Wainwright restated a neutral rating and set a $1.00 target price on shares of Cytosorbents in a report on Friday, March 15th.

Cytosorbents Price Performance

Shares of CTSO stock opened at $0.88 on Thursday. The company has a quick ratio of 1.51, a current ratio of 1.77 and a debt-to-equity ratio of 0.11. Cytosorbents has a 12-month low of $0.78 and a 12-month high of $4.29. The firm has a fifty day moving average of $0.91 and a 200-day moving average of $1.13. The firm has a market capitalization of $47.79 million, a price-to-earnings ratio of -1.38 and a beta of 0.62.

Cytosorbents (NASDAQ:CTSO) last posted its earnings results on Thursday, March 14th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. The firm had revenue of $8.67 million during the quarter, compared to analysts’ expectations of $9.29 million. Cytosorbents had a negative return on equity of 120.24% and a negative net margin of 78.43%. On average, equities research analysts forecast that Cytosorbents will post -0.36 earnings per share for the current year.

Institutional Trading of Cytosorbents

Institutional investors have recently modified their holdings of the company. Skylands Capital LLC raised its position in Cytosorbents by 10.5% in the 4th quarter. Skylands Capital LLC now owns 3,254,213 shares of the medical research company’s stock valued at $3,612,000 after buying an additional 309,543 shares during the last quarter. Avenir Corp raised its holdings in shares of Cytosorbents by 12.3% in the fourth quarter. Avenir Corp now owns 3,051,402 shares of the medical research company’s stock valued at $3,387,000 after purchasing an additional 334,005 shares during the last quarter. Neuberger Berman Group LLC raised its holdings in shares of Cytosorbents by 19.9% in the fourth quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock valued at $1,997,000 after purchasing an additional 299,103 shares during the last quarter. Sargent Investment Group LLC lifted its position in shares of Cytosorbents by 4.1% in the fourth quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock worth $1,453,000 after purchasing an additional 51,699 shares in the last quarter. Finally, Raymond James & Associates acquired a new position in Cytosorbents during the fourth quarter worth $56,000. 32.87% of the stock is currently owned by institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.